2. Search Result
Search Result
Results for "

DN 1679

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-181035
    DN1679

    		PROTACs CDK Cancer
    DN1679 is a potent, selective and orally active CRBN-dependent CDK12/13 PROTAC dual degrader. DN1679 shows DC50 of 8.8/9.8 nM (MDA-MB-231), 5.1/6.4 nM (MDA-MB-157) and 17.2/15.8 nM (MDA-MB-468) for CDK12/13. DN1679 can downregulate DNA damage response gene mRNA levels, such as ATM, ATR, BRCA1 and RAD51. DN1679 demonstrates a potent synergistic anti-tumor effect companied with Olaparib (HY-10162). DN1679 can be used for research of triple-negative breast cance .
    DN1679
  • HY-W877994
    Thalidomide-6-F-5-pip-CHO

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Thalidomide-6-F-5-pip-CHO is a synthetic E3 ligase ligand-conjugate that can be used for the synthesis of PROTACs, such as DN1679 (HY-181035) .
    Thalidomide-6-F-5-pip-CHO
  • HY-181036
    CDK12/13 ligand 3

    		Ligands for Target Protein for PROTAC CDK Cancer
    CDK12/13 ligand 3 is a CDK12/13 PROTAC ligand. CDK12/13 ligand 3 can be conjugated with E3 ligase ligand (HY-W093272) and linker to synthesize CDK12/13 PROTAC degrader DN1679 (HY-181035). CDK12/13 ligand 3 can be used for cancer research .
    CDK12/13 ligand 3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: